Actively Recruiting
Open-Label Study of Single Dose Gepotidacin to Measure Drug Levels in Breast Milk of Healthy Lactating Women
Led by GlaxoSmithKline · Updated on 2026-09-30
8
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to study the pharmacokinetics of the drug gepotidacin in healthy lactating women who are between 18 and 50 years old. The study focuses on understanding how the drug behaves in breast milk after a single oral dose, which is important for assessing the potential exposure to breastfeeding infants. It is a Phase 1, open-label trial sponsored by GlaxoSmithKline. Participants will receive a single oral dose of 3000 mg of gepotidacin. The study is designed as a single group trial without placebo, where all participants receive the drug. The main period of drug measurement covers up to 48 hours after dosing, focusing on drug concentrations in both breast milk and plasma. Participants are required to express breast milk during the study for collection. During the study, participants will be monitored closely with assessments including breast milk and plasma sampling to measure drug levels up to 48 hours post dose. Safety will also be tracked through adverse event monitoring for up to 14 days. Participants will temporarily stop breastfeeding from dosing until 72 hours afterwards but can pump and store milk for infant feeding. The total participation duration includes these procedures and follow-up for safety monitoring.
CONDITIONS
Brief Title
A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here